{"id":"https://openalex.org/W2966045481","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","title":"Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases","display_name":"Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases","publication_year":2007,"publication_date":"2007-06-20","ids":{"openalex":"https://openalex.org/W2966045481","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","mag":"2966045481"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2007.25.18_suppl.3604","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Kurzrock","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016686763","display_name":"Wallace Akerley","orcid":"https://orcid.org/0000-0002-3090-4778","observed_orcids":["https://orcid.org/0000-0002-3090-4778"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Akerley","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Hong","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053460346","display_name":"Chaan S. Ng","orcid":"https://orcid.org/0000-0001-9261-7021","observed_orcids":["https://orcid.org/0000-0001-9261-7021"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Ng","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":null,"display_name":"T. Warren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Warren","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028674788","display_name":"Kenton H. Zavitz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Zavitz","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013445952","display_name":"Chris McCage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. McCage","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111813211","display_name":"Mark A Laughlin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Laughlin","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022436659","display_name":"Luis H. Camacho","orcid":"https://orcid.org/0000-0003-1856-8641","observed_orcids":["https://orcid.org/0000-0003-1856-8641"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Camacho","raw_affiliation_strings":["UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT MD Anderson Cancer Ctr, Houston, TX; Huntsman Cancer Institute, Salt Lake City, UT; Myriad Pharmaceuticals, Inc., Salt Lake City, UT","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I2801159745"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":"18_suppl","first_page":"3604","last_page":"3604"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.7426999807357788,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.7426999807357788,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.18080000579357147,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.017400000244379044,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.7639999985694885},{"id":"https://openalex.org/keywords/colchicine-binding-site","display_name":"colchicine binding site","score":0.7670000195503235},{"id":"https://openalex.org/keywords/tubulin-polymerization-inhibitors","display_name":"tubulin polymerization inhibitors","score":0.8669999837875366},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8799999952316284},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9089999794960022},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8199999928474426},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.871999979019165},{"id":"https://openalex.org/keywords/acute-coronary-syndrome","display_name":"acute coronary syndrome","score":0.9409999847412109},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.871999979019165},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8289999961853027},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6880000233650208}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.904682993888855},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6640415787696838},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6045913696289062},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4666364789009094},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4601834714412689},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4317411780357361},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3915645182132721},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3566634953022003},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35419023036956787},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.31635215878486633},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2007.25.18_suppl.3604","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.3604","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2114237537","https://openalex.org/W2330361544","https://openalex.org/W2591248049","https://openalex.org/W2427953732","https://openalex.org/W2285394777","https://openalex.org/W2248747155","https://openalex.org/W2645659218","https://openalex.org/W2590544280","https://openalex.org/W3106639241","https://openalex.org/W3080302442"],"abstract_inverted_index":{"3604":[0],"Background:":[1],"MPC-6827":[2,29,101,223,240],"is":[3,62,224,231,241],"a":[4,19,27,64,215],"novel":[5],"competitive":[6],"inhibitor":[7],"of":[8,46,52,96,100,197,217],"tubulin":[9],"polymerization":[10],"via":[11],"the":[12,53,87,129,138],"colchicine":[13],"binding":[14],"site":[15],"and":[16,25,34,38,49,58,70,94,112,132,186,194,226],"functions":[17],"as":[18,26],"highly":[20],"potent":[21],"(1\u201310nM)":[22],"cytotoxic":[23],"agent":[24],"VDA.":[28],"inhibits":[30],"tumor":[31],"cell":[32],"growth":[33],"survival":[35],"in":[36,39,43,142,152,210,214,243],"vitro":[37],"vivo,":[40],"with":[41,104,207],"activity":[42,146],"xenograft":[44],"models":[45],"mouse":[47],"melanoma":[48],"human":[50],"cancers":[51],"ovary,":[54],"breast,":[55],"prostate,":[56],"colon":[57],"pancreas.":[59],"The":[60,166],"compound":[61],"not":[63],"substrate":[65],"for":[66,102,128],"multidrug":[67],"resistance":[68],"pumps":[69],"reaches":[71],"high":[72],"CSF":[73],"concentrations.":[74],"Methods:":[75],"Two":[76],"3+3":[77],"designed":[78],"dose-escalating":[79],"Phase":[80,244],"1":[81],"studies":[82],"were":[83,135,189,202,212],"conducted":[84],"to":[85,176,251],"define":[86],"safety,":[88],"tolerability,":[89],"maximum":[90],"tolerated":[91],"dose":[92,126,140,167],"(MTD)":[93],"PK":[95],"weekly":[97],"IV":[98],"administrations":[99],"pts":[103],"advanced":[105],"solid":[106],"malignancies":[107],"(trial":[108,116],"1;":[109],"N=46":[110],"pts)":[111],"measurable":[113],"CNS":[114],"involvement":[115],"2;":[117],"N=17":[118],"pts).":[119],"In":[120],"trial":[121],"2,":[122],"there":[123],"was":[124,147,161,170],"intrasubject":[125],"escalation":[127,157],"first":[130],"cycle":[131],"subsequent":[133],"cycles":[134],"dosed":[136],"at":[137,163,219],"highest":[139],"achieved":[141],"Cycle":[143],"1.":[144],"Antitumor":[145],"evaluated":[148],"by":[149],"RECIST":[150],"guidelines":[151],"both":[153],"studies.":[154],"Results:":[155],"Dose":[156],"proceeded":[158],"until":[159],"MTD":[160,230],"determined":[162],"3.3":[164,232],"mg/m2.":[165,233],"limiting":[168],"toxicity":[169],"acute":[171],"coronary":[172],"syndrome.":[173],"Common":[174],"mild":[175],"moderate":[177],"toxicities":[178],"included":[179],"fatigue,":[180],"headache,":[181],"flushing,":[182],"diarrhea,":[183],"nausea,":[184],"vomiting":[185],"arthralgias.":[187],"There":[188],"no":[190,195],"neurological":[191],"deficits":[192],"observed":[193],"evidence":[196],"myelosuppression.":[198],"No":[199,247],"objective":[200],"responses":[201],"observed.":[203],"Radiographic":[204],"changes":[205],"consistent":[206],"vascular":[208],"disruption":[209],"tumors":[211],"documented":[213],"number":[216],"subjects":[218],"higher":[220],"doses.":[221],"Conclusions:":[222],"safe":[225],"overall":[227],"well":[228],"tolerated.":[229],"Vascular":[234],"flow":[235],"modulation":[236],"analyses":[237],"are":[238],"ongoing.":[239],"currently":[242],"2":[245],"development.":[246],"significant":[248],"financial":[249],"relationships":[250],"disclose.":[252]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2019-08-13T00:00:00"}